No needle required: oral GLP-1 pill trims up to 12% of body weight in 36 weeks
A phase II trial of the oral GLP-1 drug aleniglipron showed it reduced body weight by up to 12.1% over 36 weeks in adults with obesity. Unlike current injectable GLP-1 medications, aleniglipron is a small molecule that can be taken orally, potentially simplifying administration and manufacturing. Researchers are advancing the drug to phase III trials, aiming to improve tolerability with a gentler dose escalation.
- Entities
- Topic: Clinical Trials
- Topic: Obesity Treatment
- Person: Tony Kushner
- Topic: Drug Development
- Company: Structure Therapeutics
This article was reported and published by egamers.io. feed.gg links to it as part of a story cluster — full text, images and rights remain with the publisher.